Orchard Therapeutics plc

NasdaqCM:ORTX Stok Raporu

Piyasa değeri: US$380.1m

Orchard Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Orchard Therapeutics CEO'su Bobby Gaspar, Mar2020 tarihinde atandı, in görev süresi 3.83 yıldır. in toplam yıllık tazminatı $ 1.45M olup, şirket hissesi ve opsiyonları dahil olmak üzere 39.6% maaş ve 60.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.16% ine doğrudan sahiptir ve bu hisseler $ 611.47K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.7 yıl ve 5.6 yıldır.

Anahtar bilgiler

Bobby Gaspar

İcra Kurulu Başkanı

US$1.4m

Toplam tazminat

CEO maaş yüzdesi39.6%
CEO görev süresi3.8yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi2.7yrs
Yönetim Kurulu ortalama görev süresi5.6yrs

Son yönetim güncellemeleri

Recent updates

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Jan 19

Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

May 09
Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Mar 10
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Orchard Therapeutics: Gene Therapy For Rare Child Disease

Aug 19

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Aug 04

Orchard Therapeutics: Shadow Of Former Glory

Jan 20

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Aug 16

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Jun 14
Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Feb 03
What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Orchard Therapeutics appoints Braden Parker as chief commercial officer

Jan 29

Orchard Therapeutics' OTL-200 wins FDA's RMAT status

Jan 14

Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022

Jan 12

Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Jan 08
Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Orchard Therapeutics' MLD gene therapy wins European nod

Dec 21

Our View On Orchard Therapeutics

Dec 17

Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Dec 11
Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study

Dec 08

Orchard Therapeutics (ORTX) Investor Presentation - Slideshow

Nov 22

CEO Tazminat Analizi

Bobby Gaspar'un ücretlendirmesi Orchard Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2023n/an/a

-US$73m

Jun 30 2023n/an/a

-US$85m

Mar 31 2023n/an/a

-US$124m

Dec 31 2022US$1mUS$573k

-US$151m

Sep 30 2022n/an/a

-US$179m

Jun 30 2022n/an/a

-US$168m

Mar 31 2022n/an/a

-US$154m

Dec 31 2021US$4mUS$605k

-US$145m

Sep 30 2021n/an/a

-US$142m

Jun 30 2021n/an/a

-US$126m

Mar 31 2021n/an/a

-US$137m

Dec 31 2020US$4mUS$543k

-US$152m

Sep 30 2020n/an/a

-US$164m

Jun 30 2020n/an/a

-US$180m

Mar 31 2020n/an/a

-US$183m

Dec 31 2019US$921kUS$344k

-US$163m

Sep 30 2019n/an/a

-US$143m

Jun 30 2019n/an/a

-US$140m

Mar 31 2019n/an/a

-US$246m

Dec 31 2018US$2mUS$338k

-US$230m

Tazminat ve Piyasa: Bobby 'nin toplam tazminatı ($USD 1.45M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 2.22M ).

Tazminat ve Kazançlar: Bobby 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Bobby Gaspar (60 yo)

3.8yrs

Görev süresi

US$1,447,526

Tazminat

Dr. Hubert Baburaj Gaspar, M.D. Ph.D. also known as Bobby, has been Chief Executive Officer at Orchard Therapeutics plc (Formerly known as Orchard Therapeutics Limited) since March 18, 2020. He serves as a...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Hubert Gaspar
CEO, Member of Scientific Advisory Board & Executive Director3.8yrsUS$1.45m0.16%
$ 611.5k
Frank Thomas
President & COO4yrsUS$1.21m0.040%
$ 153.8k
Nicoletta Loggia
Chief Technical Officer2.3yrsVeri yokVeri yok
Fulvio Mavilio
Chief Scientific Officer2yrsVeri yokVeri yok
Renee Leck
Head of Investor Relationsno dataVeri yokVeri yok
Benjamin Navon
Director of Corporate Communicationsno dataVeri yokVeri yok
John Cerio
Chief Human Resource Officerno dataVeri yokVeri yok
Robin Kenselaar
Senior VP & GM of EMEA Commercial Operations5.2yrsVeri yokVeri yok
Braden Parker
Chief Commercial Officer3yrsVeri yokVeri yok
Leslie Meltzer
Chief Medical Officer2.3yrsVeri yokVeri yok
Christopher York
Company Secretary1.9yrsVeri yokVeri yok

2.7yrs

Ortalama Görev Süresi

Deneyimli Yönetim: ORTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Hubert Gaspar
CEO, Member of Scientific Advisory Board & Executive Director7.9yrsUS$1.45m0.16%
$ 611.5k
James Arthur Geraghty
Independent Chairman5.7yrsUS$107.72k0.019%
$ 74.1k
Marc Dunoyer
Independent Non-Executive Director5.6yrsUS$71.72k0.016%
$ 62.1k
Charles Rowland
Independent Non-Executive Director5.5yrsUS$90.72k0.0054%
$ 20.5k
Donald Kohn
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Alessandra Biffi
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Brian Bigger
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Simon Jones
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Adrian Thrasher
Member of Scientific Advisory Boardno dataVeri yokVeri yok
David Williams
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Robert Wynn
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Harry Malech
Member of Scientific Advisory Boardno dataVeri yokVeri yok

5.6yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ORTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).